Dateline City:
WHITEHOUSE STATION, N.J.
Omarigliptin significantly reduced HbA1c levels compared to placebo
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the presentation of the first data from the Phase 3
clinical development program for omarigliptin, Mercks investigational
once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes. In a
study in Japanese patients, omarigliptin provided comparable efficacy
and tolerability to Mercks once-daily DPP-4 inhibitor JANUVIA
(sitagliptin) 50 mg, which is the standard starting dose for sitagliptin
in Japan.
Language:
English
Contact:
MerckMedia:Pam Eisele, +1 (267) 305-3558Michael Close, +1 (267) 305-1221 or +1 (310) 617-1067orInvestors:Justin Holko, +1 (908) 423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more